Hurdles in therapy with regulatory T cells.
Trzonkowski P., Bacchetta R., Battaglia M., Berglund D., Bohnenkamp HR., ten Brinke A., Bushell A., Cools N., Geissler EK., Gregori S., Marieke van Ham S., Hilkens C., Hutchinson JA., Lombardi G., Madrigal JA., Marek-Trzonkowska N., Martinez-Caceres EM., Roncarolo MG., Sanchez-Ramon S., Saudemont A., Sawitzki B.
Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.